NCT06176989View on ClinicalTrials.gov

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal AdenocarcinomaLocally Advanced Sinonasal AdenocarcinomaMetastatic Large-cell Neuroendocrine CarcinomaLocally Advanced Large-cell Neuroendocrine CarcinomaMetastatic Olfactory NeuroblastomaLocally Advanced Olfactory NeuroblastomaMetastatic Sinonasal Undifferentiated CarcinomaLocally Advanced Sinonasal Undifferentiated Carcinoma
Interventions
DRUG

Enasidenib

100mg PO (orally) once daily, on days 1-28 of a 28-day cycle

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH